Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT06039046
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Liposarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The study seeks to delve into the firsthand experiences of patients diagnosed with liposarcoma who partake in a separate clinical research featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. By joining this clinical study, individuals have the unique opportunity to contribute to the betterment of future liposarcoma patients and play an active role in advancing medical research.
Key Dates
- Start date
- Oct 31, 2024
- Status verified
- Sep 2023
- Primary completion
- Oct 31, 2025
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Number of patients who decide to participate in a liposarcoma clinical study [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill4159004227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 |
Find similar trials in San Francisco, CA
Related Studies
- Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaPHASE3 · Recruiting · European Organisation for Research and Treatment of Cancer - EORTC · Birmingham, Alabama
- Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsPHASE1/PHASE2 · Recruiting · Milton S. Hershey Medical Center · Birmingham, Alabama
- Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for LiposarcomasPHASE1 · Recruiting · University of Washington · Seattle, Washington